ATNM — Actinium Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $201.95m
- $125.31m
- $0.08m
Annual balance sheet for Actinium Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 9.25 | 63.6 | 77.8 | 109 | 76.7 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10.1 | 64.9 | 79.7 | 111 | 78.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.14 | 1.03 | 0.639 | 2.95 | 2.87 |
| Other Long Term Assets | |||||
| Total Assets | 11.7 | 66.4 | 80.4 | 114 | 81.4 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.34 | 4.77 | 6.84 | 10.6 | 8.49 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.03 | 5.08 | 6.84 | 47.7 | 45.1 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 5.64 | 61.3 | 73.5 | 66.5 | 36.4 |
| Total Liabilities & Shareholders' Equity | 11.7 | 66.4 | 80.4 | 114 | 81.4 |
| Total Common Shares Outstanding |